Method for controlling the fidelity and processivity of reverse transcriptase by incorporation and polymerization of nucleotide analogs accepted as substrates for the reverse transcription reaction without blocking its elongation
AssigneeCentre National de la Recherche Scientifique (CNRS)
InventorsValérie Derrien, Claude Reiss
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of nucleotide analogues, defined as molecules acceptable as substrate of the reverse-transcription response and enabling the addition of at least one supplementary nucleotide to the polynucleotide chain during synthesis to affect and/or take over control of the fidelity and execution of the reverse transcription. The invention also concerns a pharmaceutical composition containing said nucleotide analogues.
Claims30
A method of treating a condition involving reverse transcriptase in a subject, which comprises administering to the subject at least one nucleotide analog that is a substrate of reverse transcription, said nucleotide analog
- a) has a 3′—H group located on the C3′ carbon of the 2′-deoxyribose, said 3′—OH group being capable of exchanging phosphodiester bonds with the chain being formed and the next nucleotide, and
- b) does not terminate the reverse transcription.
A pharmaceutical composition comprising at least one nucleotide analog having a 3′-OH group located on the C3′carbon of the 2′-deoxyribose, said 3′-OH group being capable of exchanging phosphodiester bonds with the chain being formed and the next nucleotide, and does not terminate the reverse transcription reaction and a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.